We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Bioactivity Assays: Putting the Puzzle Together

Ulrike Herbrand joined Charles River in 2007 and works as a scientific officer for bioassays. She gained a PhD in biological sciences during her time at the Max-Planck-Institute for Molecular Physiology in Dortmund (Germany) and worked five years in postdoctoral positions at medical research centers in the field of cancer research.
  • Ulrike Herbrand, PhD, Charles River Laboratories

  • Scientific Officer, Biosafety and Bioassay Services
    Charles River
    GERMANY

  • Original Webinar Date: Tuesday, April 12, 2016

In past years, the requirement for bioactivity testing changed from later phase lot release and stability testing to additional applications like biocomparability testing for follow-on biologics, accelerated stress condition testing and confirmation of successful production scale up. Therefore a suitable bioassay is needed at a very early time point. This webinar will look at a wide variety of therapeutic proteins and illustrate some best practices in method development that results in reliable, reproducible and precise assays, and discuss which assays may be best for your product and development program.

charles_river_logo 161x42
This webinar is co-sponsored by Charles River Laboratories

Functional bioassays reflecting a drug's mechanism of action (MoA) are required by regulatory authorities when working with anti-cancer and anti-inflammatory drugs (e.g., therapeutic antibodies) to ensure efficacy and safety. In past years, the requirement for bioactivity testing changed from later phase lot release and stability testing to additional applications like biocomparability testing for follow-on biologics, accelerated stress condition testing and confirmation of successful production scale up. Therefore a suitable bioassay is needed at a very early time point.

Many times more than one assay is required since drugs such as therapeutic antibodies follow more than one MoA. The assays used need to be reliable, reproducible and precise, which is reflected by the rising acceptance of surrogate approaches whenever primary MoA assays are found to be tedious, time consuming and sometimes highly variable. With all of these things to think about finding the correct assay for your application may be challenging. Case Studies for a range of therapeutic antibodies will be presented covering the classical immunological MoA assays (e.g., ADCC, CDC and ADCP) as well as methods for therapeutic mAbs with soluble targets. These case studies will provide you with information around the options that you have and which may be most suitable for your product and development program.